Literature DB >> 1379482

A predictive model for substrates of cytochrome P450-debrisoquine (2D6).

L Koymans1, N P Vermeulen, S A van Acker, J M te Koppele, J J Heykants, K Lavrijsen, W Meuldermans, G M Donné-Op den Kelder.   

Abstract

Molecular modeling techniques were used to derive a predictive model for substrates of cytochrome P450 2D6, an isozyme known to metabolize only compounds with one or more basic nitrogen atoms. Sixteen substrates, accounting for 23 metabolic reactions, with a distance of either 5 A ("5-A substrates", e.g., debrisoquine) or 7 A ("7-A substrates", e.g., dextromethorphan) between oxidation site and basic nitrogen atom were fitted into one model by postulating an interaction of the basic nitrogen atom with a negatively charged carboxylate group on the protein. This acidic residue anchors and neutralizes the positively charged basic nitrogen atom of the substrates. In case of "5-A substrates" this interaction probably occurs with the carboxylic oxygen atom nearest to the oxidation site, whereas in the case of "7-A substrates" this interaction takes place at the other oxygen atom. Furthermore, all substrates exhibit a coplanar conformation near the oxidation site and have negative molecular electrostatic potentials (MEPs) in a part of this planar domain approximately 3 A away from the oxidation site. No common features were found in the neighbourhood of the basic nitrogen atom of the substrates studied so that this region of the active site can accommodate a variety of N-substituents. Therefore, the substrate specificity of P450 2D6 most likely is determined by the distance between oxidation site and basic nitrogen atom, by steric constraints near the oxidation site, and by the degree of complementarity between the MEPs of substrate and protein in the planar region adjacent to the oxidation site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379482     DOI: 10.1021/tx00026a010

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  18 in total

1.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

2.  Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.

Authors:  Mara Livezey; Leslie D Nagy; Laura E Diffenderfer; Evan J Arthur; David J Hsi; Jeffrey M Holton; Laura Lowe Furge
Journal:  Drug Metab Lett       Date:  2012-03

3.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

4.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

5.  Synthetic strategies to lower affinity for CYP2D6.

Authors:  R C Halliday; B C Jones; B K Park; D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

6.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

Authors:  G Smith; S Modi; I Pillai; L Y Lian; M J Sutcliffe; M P Pritchard; T Friedberg; G C Roberts; C R Wolf
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

Review 7.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

8.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 9.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 10.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.